FindTrial
Sign In

A Study on Survival and Feasibility of Chemotherapy Followed by Chemotherapy plus Radiation Therapy in Patients with Cervical Cancer

A Study on Clinical Outcome with Induction Chemotherapy Followed by Concurrent Chemoradiation in Locally Advanced Cervical Cancer in A Tertiary Care Centre - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/100828
Enrollment
54
Registered
2026-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Dr Piyush Ranjan Sahoo
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histopathology-confirmed FIGO 2018 stage IB2-IVA squamous, adenosquamous or adenocarcinoma of the cervix. 2. Medically fit to receive carboplatin and paclitaxel. 3. ECOG performance status 0 2 4. Aged 18 and over 5. Adequate renal function (defined as a GFR 60 ml per min or more using the Wright equation), liver function, and hematological profile.

Exclusion criteria

Exclusion criteria: 1. Previous pelvic radiotherapy. 2. Recurrent or metastatic disease at diagnosis. 3. Pregnancy or lactation. 4. Other synchronous malignancy. 5. Hydronephrosis, unless relieved by stenting or nephrostomy. 6. Patients who did not consent.

Design outcomes

Secondary

MeasureTime frame
1. To evaluate the progression-free survival (PFS). 2. To evaluate the best response. 3. To assess feasibility: proportion of treatment completion, treatment delays, and discontinuation. 4. To evaluate the toxicity profile (CTCAE v5.0). Timepoint: At baseline, 3 months and 6 months—

Primary

MeasureTime frame
To evaluate the objective response rate (ORR) (by RECIST v1.1)Timepoint: At baseline, 3 months and 6 months—

Countries

India

Contacts

Public ContactDr Soumya Surath Panda

Institute of Medical sciences and SUM Hospital

soumyasurathpanda@soa.ac.in8895370579

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026